Corey J. Langer, MD, Perelman Center for Advanced Medicine; Hospital of the University of Pennsylvania, discusses the prevalence of patients with non-driver non-small cell lung cancer (NSCLC). 

Related Content

ASCO Issues Update on Frontline NSCLC Treatment in Wake of Immunotherapy Approvals

March 21, 2020 08:00pm

By Audrey Sternberg

Benefit of PARP Inhibitors May Extend to Certain Tumors With IDH Mutations

March 21, 2020 12:00am

By Rachel Narozniak, MA

ACCC Creates Resources for Multidisciplinary Practices to Prepare for Growing Geriatric Cancer Population

February 25, 2020 03:30am

By Dylann Cohn-Emery

Overcoming Resistance to Osimertinib Remains Key Challenge for Treatment Strategies in NSCLC

February 20, 2020 07:30pm

By Tony Berberabe, MPH